Luis Ostrosky-Zeichner, MD

Luis Ostrosky-Zeichner, MD

University of Texas Health Science Center at Houston

Vice-Chair, Healthcare Quality Professor, Infectious Diseases

Expertise: EpidemiologyCOVID-19Infectious DiseasesAntimicrobial

Dr. Ostrosky-Zeichner is a professor of medicine and epidemiology, the Vice-Chair of Medicine for Healthcare Quality, and the director of the Laboratory of Mycology Research, at the Division of Infectious Diseases of the McGovern Medical School (a part of UTHealth). He also serves medical director for epidemiology and antimicrobial stewardship for Memorial Hermann Texas Medical Center and UT Physicians. He is also currently coordinating the CoVID-19 response for UTHealth and its affiliated hospitals and clinics.

Dr. Ostrosky-Zeichner obtained his medical degree from Universidad Nacional Autonoma de Mexico. He completed his internal medicine residency at Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, and his infectious diseases fellowship at the University of Texas Medical School at Houston and MD Anderson Cancer Center combined fellowship program.

Dr. Ostrosky-Zeichner is a fellow of the American College of Physicians, the Infectious Diseases Society of America, the Society of Healthcare Epidemiology of America, and the Academy of the European Confederation of Medical Mycology. He is a Senior Editor for the Journal of Antimicrobial Chemotherapy, as well as an editorial board member of Antimicrobial Agents and Chemotherapy and Clinical Infectious Diseases. He is Vice President of the Mycoses Study Group and Educational Consortium and a Board Member of the International Immunocompromised Host Society. He is also a past chair of the Infectious Diseases Society of America Standards and Practice Guidelines Committee and has been a consultant to the US FDA and CDC. He has advanced training and experience in medical mycology, healthcare epidemiology, emerging infections, antimicrobial stewardship, general and transplant infectious diseases, and healthcare quality and has published over 155 peer-reviewed articles on those topics.

Title

Cited By

Year

Researchers of CONTAIN study say convalescent plasma likely had benefit in early days of COVID-19; could be used early in next pandemic

COVID-19 convalescent plasma showed a likely benefit for patients early in the pandemic before remdesivir and corticosteroids were in use, according to results of a landmark study published today in JAMA that included physician-scientists at (UTHealth Houston.
13-Dec-2021 09:00:06 AM EST

Providing a safe environment for psychiatric patients during pandemic

The heart of inpatient care for psychiatric patients is socialization, group therapy and shared meals. Then COVID-19 hit with the public health warnings to isolate, socially distance, and wear masks. UTHealth had to figure out how to ride that line.
04-Nov-2020 12:30:19 PM EST

Dr. Luis Ostrosky available to talk about first Texas hospital randomized study on convalescent plasma


19-Aug-2020 10:10:14 AM EDT

Team is first in Texas to join NIH hospital study investigating efficacy of convalescent plasma for COVID-19

Using a multimillion-dollar grant from the NIH, physician-scientists at The University of Texas Health Science Center at Houston (UTHealth) will investigate whether convalescent plasma infusions can prevent the progression of COVID-19 in one of the first randomized clinical trials in the country.
19-Aug-2020 10:00:59 AM EDT

“We have other reports that are mentioning that antibodies are not everything, it's T-cell dependent as well. So, your immune system cells are trained to respond to this virus. Again, early to tell what's going to be the sort of the playout of this situation, but if it behaves like other respiratory viruses and it doesn't mutate too much.”

- Asymptomatic Transmission and Reinfection of COVID

“Combining molecular antigen and antibody testing is problematic because you're basically adding into the basket, active infection with evidence of the previous infection. And you may have overlapping patients in that same bucket.”

- Asymptomatic Transmission and Reinfection of COVID

“We generally recommend people to get tested when symptomatic and after exposure if it's important to you to be able to sort of go back to work or go back to school, we want you to wait at least five days from the day of exposure to do testing.”

- Asymptomatic Transmission and Reinfection of COVID

Available for logged-in users onlyLogin HereorRegister
close
0.07523